| Dupilumab for treating moderate to severe chronic obstructive pulmonary disease ID6235 | Technology appraisal guidance | TBC |
| Dupilumab for treating severe chronic rhinosinusitis with nasal polyposis (Review of TA648) [ID6480] | Technology appraisal guidance | |
| Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263] | Technology appraisal guidance | TBC |
| Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263] | NICE guideline | TBC |
| Durvalumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5073] | Technology appraisal guidance | |
| Durvalumab with chemoradiation for untreated unresectable locally advanced oesophageal squamous cell cancer
[ID6490] | Technology appraisal guidance | TBC |
| Durvalumab with gemcitabine and cisplatin before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating muscle-invasive bladder cancer [ID6168] | Technology appraisal guidance | |
| Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer ID6317 | Technology appraisal guidance | |
| Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma [ID2725] | Technology appraisal guidance | |
| Ectopic pregnancy and miscarriage: diagnosis and initial management | NICE guideline | TBC |
| Efgartigimod for treating generalised myasthenia gravis [ID4003] | Technology appraisal guidance | TBC |
| Efgartigimod with recombinant human hyaluronidase PH20 for treating chronic inflammatory demyelinating polyneuropathy ID6409 | Technology appraisal guidance | TBC |
| Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060] | Technology appraisal guidance | TBC |
| Empagliflozin for preventing cardiovascular events after acute myocardial infarction [ID6240] | Technology appraisal guidance | TBC |
| Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer [ID6177] | Technology appraisal guidance | |
| Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cholangiocarcinoma or pancreatic adenocarcinoma | Interventional procedures guidance | TBC |
| Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845] | Technology appraisal guidance | |
| Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable [ID6332] | Technology appraisal guidance | |
| Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more systemic treatments [ID6338] | Technology appraisal guidance | TBC |
| Epilepsies in children, young people and adults (extraordinary review) | NICE guideline | TBC |
| ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623] | Technology appraisal guidance | TBC |
| Evolocumab for preventing major cardiovascular events in people aged 50 to 79 at high risk who have not had a myocardial infarction or stroke TS ID 11920 | Technology appraisal guidance | TBC |
| Ex-situ machine perfusion devices for liver transplants: early value assessment | Health technology evaluation | |
| Exploratory economic modelling of SARS-CoV-2 viral detection point of care tests and serology tests | Diagnostics guidance | TBC |
| Familial Breast Cancer: initial assessment and genetic testing (update) | NICE guideline | |
| Favezelimab–pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after anti-PD-L1 treatment [ID6393] | Technology appraisal guidance | TBC |
| Fertility problems: assessment and treatment - update 1 and 2 | NICE guideline | TBC |
| Fezolinetant for treating vasomotor symptoms associated with the menopause [ID5071] | Technology appraisal guidance | TBC |
| Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032] | Technology appraisal guidance | TBC |
| Finerenone for treating heart failure with preserved or mildly reduced ejection fraction ID6514 | Technology appraisal guidance | TBC |
| Flow tDCS | Medtech innovation briefings | TBC |
| Fordadistrogene movaparvovec for treating Duchenne muscular dystrophy [ID6133] | Technology appraisal guidance | TBC |
| Fosdenopterin for treating molybdenum cofactor deficiency type A [ID6264] | Highly specialised technology | TBC |
| Fruquintinib for previously treated metastatic colorectal cancer ID6274 | Technology appraisal guidance | TBC |
| Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6394] | Technology appraisal guidance | |
| GID-MT567 Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain | Medical technologies guidance | TBC |
| Giroctocogene fitelparvovec for treating moderately severe to severe haemophilia A ID6312 | Technology appraisal guidance | TBC |
| Givinostat for treating Duchenne muscular dystrophy in people 6 years and over [ID6323] | Technology appraisal guidance | |
| Glaucoma - lerdelimumab (CAT-152) [ID383] | Technology appraisal guidance | TBC |
| Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse B-cell lymphoma [ID6202] | Technology appraisal guidance | |
| Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosis ID6487 | Technology appraisal guidance | |
| Guselkumab for previously treated moderately to severely active Crohn's disease ID6238 | Technology appraisal guidance | TBC |
| Guselkumab for treating moderately to severely active ulcerative colitis ID6237 | Technology appraisal guidance | |
| Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia ID1627 | Technology appraisal guidance | TBC |
| Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease [ID6343] | Technology appraisal guidance | TBC |
| Ibrutinib for treating relapsed or refractory follicular lymphoma [1251] | Technology appraisal guidance | TBC |
| Iclepertin for treating cognitive impairment associated with schizophrenia [ID6483] | Technology appraisal guidance | TBC |
| Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and over [ID547] | Technology appraisal guidance | |
| Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922] | Technology appraisal guidance | TBC |
| Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy [ID6373] | Technology appraisal guidance | TBC |